Research and Retreat Weekend 2018
One weekend, one location, lots of families, activities, learning and fun– all the weekend of
August 9-12, 2018 at the Cincinnati Great Wolf Lodge!
You’re invited to the Conference on the
Progress of Down Syndrome Research
Wednesday, March 20, 2019
We invite you to attend this great research symposium on March 20 @ 1:30pm in Mineola, New York organized by our friends at Alexander’s Angels featuring great research that has been supported by LuMind RDS. It’s a great opportunity to hear about progress in Down syndrome research directly from the researchers. The symposium is open to families and healthcare providers. Space is limited so you can reserve your spot today online at winthrop.cloud-cme.com.
The Up of Down: An Insight into the World of Down Syndrome is a Joint Provider Conference with Alexander’s Angels, Inc. and NYU Winthrop Hospital. The focus is to highlight the Down syndrome research progress and consists of speakers from a broad spectrum of specialties. Current findings will be presented by faculty from prestigious universities with affiliated hospitals on their campus. The conference will cover a wide range of topics including plans to explore a broad number of topics related to Down syndrome.
Roger Reeves, PhD.
Rethinking Alzheimer Disease in the Context of Down Syndrome
William Mobley, MD, PhD
Gene Dosage in Cellular Models of Trisomy 21
Stefan Pinter, PhD
Review the FDA Approved Study Looking at the Effect of Hypoglossal Nerve Stimulation in Treating Children Ages 10 to 21 with Down Syndrome and Significant Obstructive Sleep Apnea (OSA)
Christopher Hartnick, MD, MS
At the end of this symposium, learners should be able to:
• Discuss improvements in learning and memory in individuals with Down syndrome
• Assess and discuss why we see early onset Alzheimer’s in individuals with Down syndrome
• Explain research findings regarding cellular models
• Discuss common developmental and behavioral observations of individuals with Down syndrome
• Identify medical predispositions in individuals with Down syndrome
• Benefits of Hypoglossal Nerve Stimulation
• Discuss the effects of Down syndrome on the immune system
Please register at winthrop.cloud-cme.com
SPACE IS LIMITED. REGISTER EARLY.
NYU Winthrop Research & Academic Conference Center
101 Mineola Boulevard
Mineola, NY 11501
Registration is FREE and includes educational materials, refreshments and CME-CE credit certificate.
Shaping the Future: The State of Down Syndrome Research Today
The 35th Annual Conference at the DCU Center in Worcester, MA on March 23rd.
We’re proud to partner with the Massachusetts Down Syndrome Congress (MDSC) team to collaborate and sponsor their first research-focused event for families — Shaping the Future: The State of Down Syndrome Research Today.
This year, the community will gather to delve deep into the promising developments in Down syndrome research and the exciting potential it has for the future with session topics including:
→ innovative clinical trials and studies underway nationwide that have promise to make a difference in people’s lives
→ the latest research on sleep apnea, nutrition and obesity behavior, inclusive education, clinical care medical and neurodevelopmental conditions, speech and language pathology, and Alzheimer’s disease
→ information on the latest groundbreaking research into “silencing the extra chromosome.”
→ how to participate in Down syndrome-specific research studies, including the National Institute for Health’s DS Connect portal.
The offerings address the needs of people with Down syndrome from childhood through aging adult with useful information for self-advocates, siblings, grandparents, support providers, education and medical professionals, and researchers.
To learn more and take advantage of the early-bird registration rates, visit the conference website before March 11.
June 27-30, 2019
David Lawrence Convention Center
LuMind IDSC is proud to be the RESEARCH RALLY sponsor of the 2019 NDSC Conference. We are looking forward to reuniting with family and friends on June 27th in Pittsburg to continue collaborating in our shared goals of improving health and independence in individuals with Down syndrome. The LuMind IDSC booth is located at 100. Stop by to learn more about the exciting research, our Clinical Trial Network and the new LuMind IDSC initiatives for the Down syndrome community.
Friday, June 28, 1:30-3:00pm
Dr. James Hendrix (CSO) and Hampus Hillerstrom (CEO) are leading a presentation on Leading the Way in Down Syndrome Research: Why We Should Be Excited About The Future. The presentation will be held in the City View Room 320, 3rd Floor.
Saturday June 29th, 7:00-9:00am
Start your Saturday at the LuMind IDSC Research Rally from 7-9am with a Q&A panel featuring DSMIG clinicians, breakfast bar, and opportunities to learn more about research with rally themed games and activities. The Research Rally is located in Ballroom B & C on the 3rd Floor.
Online Registration for the Research Rally is closed at this time. If you would still like to join us Saturday morning please stop by booth 100 and sign up.
To find out more information about the conference go to the NDSC website. Our thanks to NDSC and the conference committee for their exceptional work organizing this important meeting.
LuMind IDSC will be sharing a booth with SPECS4US!!
Stop by and learn what’s new on Down syndrome research while trying on a pair of glasses with extra-wide frame fronts and a lowered bridge. If you are unable to stop by the booth you can find our live organization panel on DSDN’s Facebook or Instagram pages.
For more information on the conference contact DSDN at firstname.lastname@example.org
Join LuMind IDSC at the 34th DS ACT Convention on October 19th at the
Water’s Edge Resort and Spa
Stop by our booth to learn more about the exciting research that is getting closer to clinical trials and the new LuMind IDSC initiatives for the Down syndrome community.
James Hendrix, Ph.D., will also be speaking at the social hour at 3:45. Dr. Hendix will be presenting on how the momentum around research for Down syndrome has grown dramatically in recent years. The NIH, the pharmaceutical industry, researchers and clinicians, research-focused foundations, and families are increasingly rallying behind research to spur new treatment options for our loved ones with Down syndrome. There are many novel, promising activities in Alzheimer’s disease, sleep apnea, autoimmune conditions and more. We are entering a time where families and affiliates are now adding research to their most important topics along with education, early intervention inclusion, and advocacy.
He will also provide an update on some research advances, including work supported by the LuMind IDSC Foundation. He will also share reasons and resources for families to rally behind Down syndrome research. Dr. Hendrix is also happy to take questions on Down syndrome research.
To find out more information about the conference, go to the DS ACT website at mydsact.org Our thanks to DS ACT for inviting LuMind IDSC and for the conference committee for their exceptional work organizing this conference.
The 2019 North Carolina Down Syndrome Conference covers the lifespan of an individual with Down syndrome and is a valuable resource serving all audiences. The conference includes a plenary speaker, resource exhibits, networking lunch, and 18 breakout sessions that bring information and resources to families, educators, healthcare providers, and older teens and adults with Down syndrome.
The development of the next generation of Alzheimer’s disease treatments is among the most important health needs worldwide, but presents huge challenges. The goal of the meeting is to bring together today’s worldwide leaders in the treatment of Alzheimer’s disease to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer’s disease treatments.
Clinical trial teams from worldwide centers will report on their efforts to identify new biomarkers of disease as well as more sensitive clinical assessment tools to identify those at risk for AD, to predict progression, and assess the effectiveness of new treatments.
The future of clinical trials may lie in revisiting all drugs known to be safe and evaluate their relevance in AD treatment. We learned at CTAD 2018 of the importance of non-pharmaceutical trials and that anti-amyloid treatment for AD should begin early on in the disease process. Furthermore we also learned more of another pathway with Tau Biomarkers, and their implications for AD along with combination therapeutics and phase 3 clinical trials results. Again in 2019 Clinical teams will present their population studies on subjects in the early stage of the disease or even at the asymptomatic stage.
CTAD 2019 will highlight the latest on trying to get these trials off the ground.
Overall, the aim of the conference is to overcome the hurdles and speed the development of effective treatments.